ACE2 and cardiovascular disorder: Females theoretically have a double dose of ACE2, which may compensate for SARS-CoV-2 mediated loss of membrane ACE2 and alleviate aberrant RAS activity and related cardiovascular diseases (Tu et al., 2020; Viveiros et al., 2021).